SL
INTS icon

Sentinus LLC’s Intensity Therapeutics INTS Stock Holding History

Sentinus LLC’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Buy
26,723
+3,429
+15% +$16.1K 0.01% 641
2026
Q1 		$137K Buy
23,294
+3,458
+17% +$28.2K 0.01% 574
2025
Q4 		$203K Buy
19,836
+589
+3% +$5.97K 0.02% 521
2025
Q3 		$117K Buy
19,247
+11,274
+141% +$80.6K 0.03% 236
2025
Q2 		$61.2K Buy
7,973
+6,881
+630% +$141K 0.02% 209
2025
Q1 		$53.8K Buy
+1,092
New +$60.7K 0.02% 193
2024
Q4 		– Sell
-757
Closed -$72.3K – 188
2024
Q3 		$72.3K Buy
757
+223
+42% +$24.8K 0.02% 186
2024
Q2 		$65.4K Sell
534
-618
-54% -$70.1K 0.02% 181
2024
Q1 		$150K Buy
+1,152
New +$138K 0.05% 165

Other funds holding INTS

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Sentinus LLC's INTS Position: Q2 2026 in Review

Sentinus LLC increased its Intensity Therapeutics (INTS) stake by 15% in Q2 2026, buying an estimated $16.1K and bringing the position to 26,723 shares worth $110K. The position accounts for 0.01% of the portfolio, ranked #641.

Sentinus LLC first reported a position in INTS in Q1 2024 and has held it in 9 quarters since. The position peaked at $203K in Q4 2025. 17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Sentinus LLC held 26,723 shares of Intensity Therapeutics worth $110K as of Q2 2026.
  • Sentinus LLC bought 3,429 Intensity Therapeutics shares in Q2 2026, an estimated $16.1K.
  • Intensity Therapeutics made up 0.01% of Sentinus LLC's portfolio in Q2 2026, its #641 holding.
  • Sentinus LLC first reported a position in Intensity Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Sentinus LLC's Intensity Therapeutics position peaked at $203K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Sentinus LLC's 13F filing for Q2 2026, filed 11 Aug 2026.